Press Releases

SAN ANTONIO, TEXAS—April 18, 2007—Seno Medical Instruments, Inc., a San Antonio company engaged in the development of medical devices announces the election of J. Arturo Bonilla, M.D to its Board of Directors. Dr. Bonilla, a San Antonio surgeon well known for founding the Microtia-Congenital Ear Institute, will lend his business leadership skills to advance Seno Medical’s patented breast cancer diagnostic technology.

Seno Medical Instruments, Inc. was formed in 2005 to commercialize a new modality in cancer screening and diagnosis; opto-acoustic imaging. To further the development of this potentially life-saving technology, the corporation is assembling a team of experts in the field of breast cancer detection, product application and protocol design.

“Dr. Bonilla has been instrumental in securing support for this technology from esteemed members of the greater San Antonio medical community. As an entrepreneur with a successful record of investing, Dr. Bonilla proves to be an invaluable resource to Seno as we launch our innovative cancer diagnostic tools to market,” said Janet Campbell, Seno Medical CEO. “I feel very fortunate that Dr. Bonilla has agreed to join our Board of Directors.”

Dr. Bonilla says he is impressed by the company’s leadership and is encouraged by his fellow physicians” reactions to the technology. “When I saw the support from worldwide leading experts in medicine, especially radiology and oncology, I knew that we had something very special here,” said Bonilla. “The experience and integrity of this company and the hard work of all its staff has left me with no doubt this breakthrough technology will soon be commonplace. This in turn will save many lives.“

Dr. Bonilla is a pediatric ear, nose and throat surgeon based in San Antonio. Dr. Bonilla was also co-owner of the Pediatric Ear, Nose & Throat Institute of South Texas, and is one of only four such surgeons in South Texas. In addition to being the founder of the Microtia-Congenital Ear Institute, he has been featured in numerous media reports for his work in correcting birth defects of the ear. He has developed one of the largest individual ear reconstructive practices in the world. He is the co-founder and president of the Skin Concepts Laser Centers, a cosmetic hair and skin treatment center. Dr. Bonilla is also an investor and was a past member of the governing board of the Methodist Ambulatory Surgery Center at Stone Oak in San Antonio. He is also an investor and governing board member of the Physicians Ambulatory Surgery Centers, one of the largest physician-owned ambulatory surgery centers in the country. He is also a past member of the Medical School Interview Committee at The University of Texas Health Science Center at San Antonio.

Dr. Bonilla is a graduate of St. Mary’s University in San Antonio and received his medical degree from the University of Texas Health Science Center at Houston. He completed his general surgery residency at Methodist Hospital in Dallas and his residency in otolaryngology at the State University of New York. He completed his pediatric ear, nose & throat surgery subspecialty training at the Children’s Hospital of Pittsburgh.

SAN ANTONIO, TEXAS—February 26, 2007—Seno Medical Instruments, Inc.,, a San Antonio company engaged in the development of medical devices announces the appointment of Robert I. Kramer, M.D., FAAP to Chairman of its Scientific Advisory Committee.

SENO MEDICAL INSTRUMENTS, INC. Nominates DR. ROBERT KRAMER TO HEAD SCIENTIFIC ADVISORY COMMITTEE

SAN ANTONIO, TEXAS — February 26, 2007 – Seno Medical Instruments, Inc., a San Antonio company engaged in the development of medical devices announces the appointment of Robert I. Kramer, M.D., FAAP to Chairman of its Scientific Advisory Committee. Dr. Kramer, founding member of the Susan G. Komen Advisory Board, is highly regarded for his work in the field of pediatrics and for his support of cancer research and treatment.

Seno Medical Instruments, Inc. was formed in 2005 to commercialize a new modality in cancer screening and diagnosis: opto-acoustic imaging. To further the development of this potentially life-saving technology, the corporation is assembling a team of experts in the field of breast cancer detection, product application and protocol design.

“Dr. Kramer has a deep commitment to the field of breast cancer. He has worked with many early stage companies focused on medical advancement. His extensive experience and knowledge in biotechnology and medical devices is invaluable to us,” said Janet Campbell, Seno Medical CEO. “I feel very fortunate that Dr. Kramer has agreed to assume this responsibility in leading the Advisory Committee.”

Dr. Kramer is a retired professor of pediatrics and pulmonology from UT Southwestern Medical Center in Dallas, Texas. He was the founding medical director of the Division of Pulmonology and Cystic Fibrosis Research Center at the Children’s Medical Center in Dallas. Following his retirement, he became Chairman of the Department of Pediatrics at Baylor University Medical Center. He was the national medical director of the healthcare consulting division of Coopers & Lybrand and in this capacity had his initial introduction to the business of the life science industry. Dr. Kramer is a member of the Board of Directors and Advisory Boards of several early-stage life science companies. He is a member of the External Advisory Committee of the Department of Biomedical Engineering at the University of Texas, Austin.

Dr. Kramer is a native of Rhode Island and a graduate of Tufts University Medical School with a pediatric residency completed at Yale University School of Medicine. He holds an Executive MBA from Harvard Business School.

(San Antonio, TX, January 31, 2007) – Seno Medical Instruments, Inc., a company engaged in the development of medical devices, announced the completion during December 2006 of its Series A Preferred Stock offering.  The San Antonio-based company received aggregate proceeds in the amount of $6.0 million from the offering.  This funding allowed the company to start pursuing the development and commercialization of its innovative, patented opto-acoustic technology.

The platform technology, which combines light and sound to produce high contrast images for cancer detection, has a multitude of potential applications. Initial applications will target the research and breast cancer markets.  The first clinical applications, breast cancer diagnosis and screening, will target a market estimated to be $5.9B (North America only).  Future applications include ovarian, prostate, colorectal, bladder, and melanoma cancers, as well as a multitude of other non-cancer applications.

The company’s Chief Executive Officer, Janet Campbell, is one of the first female CEOs in the breast cancer imaging industry.  Ms. Campbell stated, “This funding milestone is cause for celebration among company founders and investors.  The prominence of our Series A investors in the medical field is yet another validation of this potentially ground-breaking technology.”

SAN ANTONIO, TEXAS — August 4, 2006 – Seno Medical Instruments, Inc., a San Antonio medical device company specializing in the early detection of cancer, announced today Joseph C. McNay of Boston, Massachusetts will join its Board of Directors. McNay joins Seno Medical Instruments at an exciting time for the company. Seno recently announced it has received $3 (M) million dollars in funding to launch commercial operations. This funding will allow the company to further develop patented laser optoacoustic breast imaging technology for commercial use by doctors and hospitals around the world.

McNay currently serves as President of the Boston Securities Analyst Society (BSAS), a non-profit association founded as a forum for the exchange of information in the investment community. It currently serves over 4,500 members. McNay is also the Chairman and Chief Investment Officer and Managing Principal of Essex Investment Management Company, LLC. Prior to founding Essex in 1976, he was Executive Vice President and Director of Endowment Management and Research Corp. for nine years.

McNay, esteemed in the global business community for his investment expertise, is also well-regarded as a leader in the medical community. He currently serves as a Trustee of the Dana Farber Cancer Institute and on the Investment Committee of Children’s Hospital Boston. McNay is head of the Advisory Committee for the Juda Folkman Foundation, which supports Dr. Juda Folkman for his research at Children’s Hospital Boston. In addition to serving on Seno Medical’s Board of Directors, he will continue to serve on the Board of Directors at the biotechnology company, ReGenRx Biopharmaceuticals, Inc.

McNay is admired for sharing his investment knowledge as a Trustee of National Public Radio, the Boston Ballet and the Woods Hole Oceanographic Institution. He is a Yale University graduate with an M.B.A. from the Wharton School of Finance.

“As we persist in growing Seno Medical Instruments, we continue to look for outstanding people like Joe McNay to bring levels of expertise we can depend on to reach our goals,” said Janet Campbell, Seno Medical CEO. “We anticipate Joe’s extensive experience in both investment and medical arenas to positively impact our future growth.”

(San Antonio, TX, June 29, 2006) – Seno Medical Instruments, Inc. is one step closer to moving breakthrough breast cancer diagnostic technology to the global marketplace. The San Antonio-based medical device company announced it has received more than $3 (M) dollars to launch commercial operations. This funding will allow the company to further develop patented laser optoacoustic breast imaging technology for commercial use by doctors and hospitals around the world. The target market for the breast cancer diagnostic technology is estimated to be $5.9 (B) billion dollars in North America alone.

Validation of the science has been confirmed repeatedly through peer review and more than $13 (M) million dollars in funding from the National Institutes of Health, the Department of Defense and the National Cancer Institute. The NCI recently awarded Seno Medical’s development partner, Fairway Medical Technologies, Inc., with a $1.1 (M) million dollar grant to expand the technology for prostate cancer applications.

Seno Medical’s development partner, Fairway Medical Technologies has been collaborating with the University of Texas Medical Branch in Galveston to further develop its proof-of -concept. The platform technology, which fuses light and ultrasound to create strong contrast between normal and cancerous tissues, has a multitude of potential applications. They include the diagnosis of ovarian, prostate, colorectal, bladder, and melanoma cancers. The technology will also have cardiovascular applications.

Seno’s CEO, Janet Campbell is one of the first woman CEO’s in the breast cancer imaging industry. She says, “More than 1.2 million women and men around the world will be diagnosed with breast cancer according to the World Health Organization. Our technology has the ability to detect cancer in its earliest stages without breast compression or exposure to x-ray. We are tremendously excited about the opportunity to bring this technology to patients everywhere.”

Ron Branstetter, President and COO of Seno Medical said, “I am excited about the quality of the technical and business teams we have assembled so that we may soon offer this state-of-the-art technology to physicians, hospitals and mammography centers.”

Ms. Campbell most recently served as President and COO of InforMedix, Inc, where she oversaw the company’s IPO and successfully hired the team that launched the company’s first commercial product. She also served as Chairman of the Board of Directors for Vascular Genetics, Inc. Ms. Campbell received her BA from the University of Missouri and her MBA from The Johns Hopkins University.

Seno is also pleased to announce that Dr. Robert Kramer, a recent nominee for surgeon general and a founding Board Member of the Susan G. Komen Foundation, has accepted the nomination to lead the Scientific Advisory Board. The Scientific Advisory Board will be comprised of experts in the field of breast cancer and will be actively involved in the company.

If you would like to know more about this breakthrough technology or would like to interview Seno Medical CEO, Janet Campbell, please contact Liz Bradford at 214-202-8830.